Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,679Revenue (TTM) $M15.0Net Margin (%)-822.0Altman Z-Score54.5
Enterprise Value $M4,292EPS (TTM) $-1.4Operating Margin %-861.9Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.1Pre-tax Margin (%)-822.0Higher ROA y-yN
Price/Book12.310-y EBITDA Growth Rate %--Quick Ratio14.6Cash flow > EarningsY
Price/Sales3125-y EBITDA Growth Rate %--Current Ratio14.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-26.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-28.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M86.8ROIC % (ttm)-290.3Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NBIXGeorge Soros 2016-06-30 Sold Out -0.01%$39.55 - $51.97
($45.94)
$ 53.9417%Sold Out0
NBIXGeorge Soros 2016-03-31 Buy 0.01%$32.19 - $56.57
($40.01)
$ 53.9435%New holding9,400
NBIXGeorge Soros 2013-09-30 Sold Out -0.03%$10.6 - $16.7
($13.79)
$ 53.94291%Sold Out0
NBIXGeorge Soros 2013-06-30 Buy 0.03%$10.9 - $13.57
($12.28)
$ 53.94339%New holding200,000
NBIXJoel Greenblatt 2012-12-31 Sold Out -0.13%$6.88 - $8.66
($7.6)
$ 53.94610%Sold Out0
NBIXJoel Greenblatt 2012-06-30 Add0.03%$6.31 - $8.06
($7.18)
$ 53.94651%Add 23.80%259,903
NBIXGeorge Soros 2012-06-30 Sold Out -0.02%$6.31 - $8.06
($7.18)
$ 53.94651%Sold Out0
NBIXJoel Greenblatt 2012-03-31 Buy 0.15%$7.33 - $9.79
($7.95)
$ 53.94578%New holding209,930
NBIXGeorge Soros 2012-03-31 Buy 0.02%$7.33 - $9.79
($7.95)
$ 53.94578%New holding150,000
NBIXGeorge Soros 2011-12-31 Sold Out -0.0018%$5.5 - $8.58
($6.76)
$ 53.94698%Sold Out0
NBIXGeorge Soros 2011-09-30 Reduce$5.59 - $8.44
($6.71)
$ 53.94704%Reduce -23.93%17,800
NBIXGeorge Soros 2011-06-30 Add$6.82 - $8.3
($7.54)
$ 53.94615%Add 90.24%23,400
NBIXGeorge Soros 2011-03-31 Add$6.47 - $7.84
($7.2)
$ 53.94649%Add 23.00%12,300
NBIXGeorge Soros 2010-12-31 Buy $5.99 - $8.53
($7.63)
$ 53.94607%New holding10,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NBIX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Lloyd-Smith MalcolmChief Regulatory Officer 2016-09-01Sell9,000$507.88view
OBrien Christopher FlintChief Medical Officer 2016-08-15Sell12,500$48.7310.69view
Nevinny Corinne HDirector 2016-08-08Sell5,000$48.5411.12view
Lloyd-Smith MalcolmChief Regulatory Officer 2016-05-31Sell9,000$507.88view
OBrien Christopher FlintChief Medical Officer 2016-05-31Sell12,500$507.88view
POPS RICHARD FDirector 2016-05-25Sell15,000$46.7215.45view
OBrien Christopher FlintChief Medical Officer 2016-05-16Sell25,000$4519.87view
Gano KyleChief Business Development Off 2016-04-11Sell41,770$44.0222.54view
OBrien Christopher FlintChief Medical Officer 2016-04-06Sell25,000$4519.87view
OBrien Christopher FlintChief Medical Officer 2016-02-03Sell1,500$38.0141.91view

Quarterly/Annual Reports about NBIX:

News about NBIX:

Articles On GuruFocus.com
Meridian Funds Comments on Neurocrine Biosciences Aug 31 2015 
Meridian Contrarian Fund Annual Report 2015 Aug 31 2015 
Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
5 Strong Healthcare Stocks For 2012 Mar 24 2012 
Consider These 5 Healthcare Stocks Now Mar 21 2012 
Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 

More From Other Websites
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Sep 23 2016
Blue Jay Capital Betting On Big Returns From These Healthcare Stocks Sep 22 2016
Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia Sep 17 2016
Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor... Sep 17 2016
Neurocrine Biosciences to Present at the Morgan Stanley Global Healthcare Conference Sep 07 2016
Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference Sep 01 2016
Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor... Aug 31 2016
Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA™ for VMAT2 Inhibitor... Aug 31 2016
Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia Aug 29 2016
Neurocrine Submits New Drug Application for Valbenazine for Treatment of Tardive Dyskinesia Aug 29 2016
ETF’s with exposure to Neurocrine Biosciences, Inc. : August 12, 2016 Aug 12 2016
NEUROCRINE BIOSCIENCES INC Financials Aug 11 2016
Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : NBIX-US :... Aug 11 2016
NBIX: NDA for Valbenazine in Tardive Dyskinesia Set to be Filed; Data From Tourette Syndrome Trials... Aug 04 2016
Edited Transcript of NBIX earnings conference call or presentation 3-Aug-16 9:00pm GMT Aug 04 2016
Neurocrine reports 2Q loss Aug 03 2016
Neurocrine reports 2Q loss Aug 03 2016
Neurocrine Biosciences Reports Second Quarter 2016 Results Aug 03 2016
NEUROCRINE BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 03 2016
Neurocrine Biosciences Reports Second Quarter 2016 Results Aug 03 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)